Drug
Smoflipid 20
Smoflipid 20: highest development phase Phase 3, developed by Fresenius Kabi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Fresenius Kabi
Trials
| Drug | Phase | Indication |
|---|---|---|
| Smoflipid 20% (investigational lipid for parenteral nutrition) NCT02579265 | Phase 3 | Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days |
Latest
No recent events.
Follow Smoflipid 20 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.